Exhibit 10.1

H.C. Wainwright & Co., LLC

430 Park Avenue, 4th Floor

New York, New York 10022

March 14, 2017

Ladies and Gentlemen:

Pursuant to the terms and subject to the conditions contained in the at the
Market Offering Sales Agreement between Anthera Pharmaceuticals, Inc. (the
“Company”), and H.C. Wainwright & Co., LLC (“Wainwright”) dated April 21, 2016
(the “Agreement”), the Company and Wainwright agree that the Agreement is hereby
amended so that the aggregate offering price of shares of Common Stock subject
to the Agreement pursuant to Section 1 thereof shall be $23,000,000.

Other than as set forth above the Agreement remains in full force and effect.

Capitalized terms used but not otherwise defined herein have the meanings set
forth in the Agreement.

[remainder of page left blank intentionally.]

--------------------------------------------------------------------------------

If the foregoing correctly sets forth the understanding between the Company and
Wainwright, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between the Company
and Wainwright.

 

Very truly yours, H.C. WAINWRIGHT & CO., LLC By:   /s/ Edward D. Silvera Name:  
Edward D. Silvera Title:   COO

ACCEPTED as of the date

first-above written:

ANTHERA PHARMACEUTICALS, INC. By:   /s/ May Liu Name:   May Liu Title:  

Senior Vice President, Finance and

Administration